SCHEMBL20121605

SCHEMBL20121605

Cc1ccc(Nc2c(-c3ccc(F)cc3)nc3n2CCN(C(=O)C(C)(Cc2cccc(N)c2)NC(=O)OC(C)(C)C)C3)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 13/20 0.63
CYP3A4 P08684 2/20 0.38
CCNT1 O60563 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CDK9 P50750 1/20 0.34
CCNA1 P78396 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
JAK2 O60674 1/20 0.33
JAK3 P52333 1/20 0.33
PTK2 Q05397 1/20 0.33
TGFBR1 P36897 1/20 0.33
CSNK1D P48730 2/20 0.33
CSNK1E P49674 2/20 0.33
BACE1 P56817 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2068503 0.85 KCNH2 (0.57) KCNH2CYP3A4
SCHEMBL12952019 0.81 KCNH2 (0.71) KCNH2CYP3A4TGFBR1
SCHEMBL15760198 0.80 KCNH2 (0.56) KCNH2CYP3A4CCNT1CCNA2CDK2
SCHEMBL2068778 0.79 KCNH2 (0.81) KCNH2CYP3A4TGFBR1CSNK1DCSNK1E
SCHEMBL20121186 0.79 KCNH2 (0.81) KCNH2CYP3A4TGFBR1CSNK1DCSNK1E
SCHEMBL17626302 0.78 KCNH2 (0.59) KCNH2CYP3A4CSNK1DCSNK1E
SCHEMBL17626366 0.78 KCNH2 (0.61) KCNH2CYP3A4CSNK1DCSNK1E
SCHEMBL15760160 0.78 KCNH2 (0.77) KCNH2CYP3A4CYP2C9CYP2C19TGFBR1
SCHEMBL2068261 0.78 KCNH2 (1.00) KCNH2CYP3A4TGFBR1CSNK1DCSNK1E
SCHEMBL2069056 0.77 KCNH2 (0.84) KCNH2CYP3A4TGFBR1CSNK1DCSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963454-B2 Compounds and compositions for the treatment of parasitic disease NOVARTIS AG (CH) 2018-05-08 US disclosed